ArticleAnnals of medicine2025
Optimizing recovery in orthognathic surgery: the cohort study of impact of rocuronium-sugammadex on extubation and perioperative outcomes.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Response to letter regarding 'Optimizing recovery in orthognathic surgery: the cohort study of impact of rocuronium-sugammadex on extubation and perioperative outcomes'.Annals of medicine · 2025Article
- Regarding: 'Optimizing recovery in orthognathic surgery: the cohort study of impact of rocuronium-sugammadex on extubation and perioperative outcomes'.Annals of medicine · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOrthognathic surgery (OGS) often necessitates deep neuromuscular blockade to optimize surgical conditions, but the choice of neuromuscular blocking and reversal agents may influence postoperative recovery. Rocuronium, when reversed with sugammadex, offers rapid neuromuscular recovery compared to traditional cisatracurium and neostigmine. This study evaluates the impact of rocuronium/sugammadex versus cisatracurium/neostigmine on perioperative outcomes in OGS.
methodsThis retrospective cohort study analyzed 361 patients who underwent OGS between 2019 and 2022. Patients received either cisatracurium with neostigmine (
resultsPatients in the rocuronium/sugammadex group demonstrated significantly shorter extubation times (25.0 [15.0-77.5] vs. 55.0 [25.0-85.0] min,
conclusionsThe use of rocuronium with sugammadex in OGS is associated with enhanced postoperative recovery, including reduced extubation time, decreased intraoperative blood loss, and shorter hospital stay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.